Rate My Professor Evie Jackson

Dr Evie Jackson is a Postdoctoral Fellow in the School of Biomedical Sciences and Pharmacy within the College of Health, Medicine and Wellbeing at the University of Newcastle, Australia. An early career researcher, she was awarded her PhD in Medical Biochemistry by publication in December 2023 from the University of Newcastle, building on her Bachelor of Biomedical Science and Honours degrees from the same university. Since 2018, Jackson has been an integral part of the Cancer Signalling Research Group led by Professor Matthew Dun, affiliated with the University of Newcastle and Hunter Medical Research Institute. Her expertise lies in DIPG in vitro modelling and biochemical analysis, employing cellular and molecular biology techniques alongside high-resolution quantitative proteomics to uncover novel treatments for the aggressive pediatric brain cancer diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG).

Jackson's research has identified key therapeutic vulnerabilities, such as disrupting mitochondrial function with ONC201 and targeting compensatory PI3K/mTOR pathways with paxalisib, providing preclinical support for the international PNOC022 clinical trial. Notable publications include 'PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma' (Journal of Clinical Investigation, 2024), 'ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma' (Cancer Research, 2023), and 'A review of current therapeutics targeting the mitochondrial protease ClpP in diffuse midline glioma, H3 K27-altered' (Neuro-Oncology, 2024). She holds the Col Reynolds Fellowship - Early Career from The Kids' Cancer Project (2024-2026) and received the Marit Mary Swenson Award for Pediatric DMG/DIPG in 2023. Through her work, Jackson advances precision medicine for these devastating childhood cancers.